(NASDAQ: HURA) Tuhura Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Tuhura Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast HURA's revenue for 2028 to be $2,665,499,279, with the lowest HURA revenue forecast at $2,665,499,279, and the highest HURA revenue forecast at $2,665,499,279. On average, 1 Wall Street analysts forecast HURA's revenue for 2029 to be $5,437,098,041, with the lowest HURA revenue forecast at $5,437,098,041, and the highest HURA revenue forecast at $5,437,098,041.
In 2030, HURA is forecast to generate $8,318,800,040 in revenue, with the lowest revenue forecast at $8,318,800,040 and the highest revenue forecast at $8,318,800,040.